scispace - formally typeset
N

Nathaniel S. Schocker

Researcher at University of Texas at El Paso

Publications -  14
Citations -  262

Nathaniel S. Schocker is an academic researcher from University of Texas at El Paso. The author has contributed to research in topics: Chagas disease & Glycan. The author has an hindex of 7, co-authored 13 publications receiving 214 citations. Previous affiliations of Nathaniel S. Schocker include University of Texas System & Massachusetts Institute of Technology.

Papers
More filters
Journal ArticleDOI

Enhancing glycan isomer separations with metal ions and positive and negative polarity ion mobility spectrometry-mass spectrometry analyses

TL;DR: Ims-MS results showed significant differences for the glycan structural isomers when analyzed in positive and negative polarity and complexed with different metal cations, and suggest that specific metal ions or ion polarities could be used to target and baseline separate glycan isomers of interest with IMS-MS.
Journal ArticleDOI

An α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major.

TL;DR: It is proposed that NGP5B is an attractive candidate for the study of potential synthetic α-Gal-neoglycoprotein-based vaccines against L. major, and a robust humoral and cellular immune response with production of high levels of protective lytic anti-α-Gal antibodies and induction of Th1 cytokines is observed.
Journal ArticleDOI

Potential use of synthetic α-galactosyl-containing glycotopes of the parasite Trypanosoma cruzi as diagnostic antigens for Chagas disease

TL;DR: A synthetic glycoarray containing non-reducing α-galactopyranosyl moieties related to mucin O-glycans of the parasite Trypanosoma cruzi revealed the disaccharide Galα(1,3)Galβ as the immunodominant glycotope, which may be employed as a diagnostic antigen for Chagas disease.
Journal ArticleDOI

Synthesis of Galα(1,3)Galβ(1,4)GlcNAcα-, Galβ(1,4)GlcNAcα- and GlcNAc-containing neoglycoproteins and their immunological evaluation in the context of Chagas disease

TL;DR: The results indicate that the synthetic Galα (1,3)Galβ(1,4)GlcNAcα-BSA glycotope coupled to a carrier protein could be a potential diagnostic and vaccine candidate for ChD and highlights the importance of the terminal Galα moiety for recognition by Ch anti-α-Gal Abs and the lack of Abs against nonself Galβ( 1,4), Glcnacα and Glc NAcα glycotopes.